NCT04082533View on ClinicalTrials.gov

Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
PainArthrofibrosisOsteoarthritis, Knee
Interventions
DRUG

Hydrocortisone

Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.

DRUG

Dextrose 5% in water (D5W)

Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.

Trial Locations (1)

10021

Hospital for Special Surgery, New York

All Listed Sponsors
lead

Hospital for Special Surgery, New York

OTHER